Below are the most recent publications written about "Carcinoma, Papillary" by people in Profiles.
-
Zantut-Wittmann DE, Barreto IS, Laus AC, Moreno DA, Moma CA, Maia FFR, Assump??o LVMD, Reis RM. PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma. Mol Cell Endocrinol. 2023 06 15; 570:111931.
-
Comiskey DF, He H, Liyanarachchi S, Sheikh MS, Hendrickson IV, Yu L, Brock PL, de la Chapelle A. Characterizing the function of EPB41L4A in the predisposition to papillary thyroid carcinoma. Sci Rep. 2020 11 17; 10(1):19984.
-
Wang Y, Liyanarachchi S, Miller KE, Nieminen TT, Comiskey DF, Li W, Brock P, Symer DE, Akagi K, DeLap KE, He H, Koboldt DC, de la Chapelle A. Identification of Rare Variants Predisposing to Thyroid Cancer. Thyroid. 2019 07; 29(7):946-955.
-
Roch AM, Schneider J, Carr RA, Lancaster WP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM, Ceppa EP. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma? J Surg Oncol. 2019 May; 119(6):777-783.
-
Liao H, Khan A, Miron PM, Cornejo KM. Mammary Analogue Secretory Carcinoma of the Thyroid Mimicking Locally Advanced Papillary Thyroid Carcinoma: A Rare Case Report. Int J Surg Pathol. 2018 Aug; 26(5):459-463.
-
Goyal N, Pakdaman M, Kamani D, Caragacianu D, Goldenberg D, Randolph GW. Mapping the distribution of nodal metastases in papillary thyroid carcinoma: Where exactly are the nodes? Laryngoscope. 2017 08; 127(8):1959-1964.
-
Roch AM, Rosati CM, Cioffi JL, Ceppa EP, DeWitt JM, Al-Haddad MA, House MG, Zyromski NJ, Nakeeb A, Schmidt CM. Intraductal papillary mucinous neoplasm of the pancreas, one manifestation of a more systemic disease? Am J Surg. 2016 Mar; 211(3):512-8.
-
Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, Song C, Castellanos-Rizaldos E, Makrigiorgos GM, Kurebayashi J, Nose V, Van Hummelen P, Bronson RT, Vinco M, Giordano TJ, Dias-Santagata D, Pandolfi PP, Nucera C. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget. 2015 Dec 15; 6(40):42445-67.
-
Cornejo KM, Dong F, Zhou AG, Wu CL, Young RH, Braaten K, Sadow PM, Nielsen GP, Oliva E. Papillary renal cell carcinoma: correlation of tumor grade and histologic characteristics with clinical outcome. Hum Pathol. 2015 Oct; 46(10):1411-7.
-
Roch AM, Barron MR, Tann M, Sandrasegar K, Hannaford KN, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM. Does PET with CT Have Clinical Utility in the Management of Patients with Intraductal Papillary Mucinous Neoplasm? J Am Coll Surg. 2015 Jul; 221(1):48-56.